Trials / Completed
CompletedNCT01018966
Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
Phase I Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days) |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-03-01
- Completion
- 2005-04-01
- First posted
- 2009-11-25
- Last updated
- 2017-01-30
Source: ClinicalTrials.gov record NCT01018966. Inclusion in this directory is not an endorsement.